Repatha is a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. Amgen has announced a price reduction for Repatha (evolocumab), bringing the list price of the therapy to $5,850 per year, ...

Amgen announced that as part of the company's commitment to improve patient affordability for an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and ...

Amgen announced that all Repatha (evolocumab) devices are now available at a 60% reduced list price. This includes the pre-filled syringe, the SureClick autoinjector, and the Pushtronex device, an ...

Following a price cut for its Repatha SureClick auto-injector in October, Amgen Inc. (AMGN) announced on Monday it is slashing the price of all Repatha devices by 60% to $5,850 per year. Repatha, one ...

Sanofi SNY and partner Regeneron Pharmaceuticals, Inc. REGN announced a 60% cut in the U.S. list price of their PCSK9 inhibitor, Praluent, following a similar action last year by rival Amgen, Inc.

THOUSAND OAKS, Calif., Amgen today announced the submission of an application to the U.S. Food and Drug Administration (FDA) seeking approval of a single-dosing option for the monthly administration ...

Most Medicare Part D plans include coverage for Repatha, though specific coverage details can vary among plans. Out-of-pocket costs for Repatha under Medicare Part D typically average around $49 per ...